Itabmed Completes Series A-Round Financing After Spin-Off
12/01/21, 9:00 AM
Location
Round Type
series a
ITabMed today announced it has completed the spin-off iTAbTM (immunotherapy antibody) platform and closed $20M Series A-round financing. Earlier in this year, Evive Biotech (formerly Generon BioMed Ltd) and Dr. Xiaoqiang Yan formed a joint venture and established ITabMed Ltd. with the full support from Evive and its shareholders
Company Info
Location
shanghai, shanghai, china
Additional Info
ITabMed is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is registered in Lin Gang Sci-Tech City, Shanghai. It was a spin-off entity from the former “Generon BioMed Ltd.”. The company is focused on immunotherapy drug research and development to treat cancer. (www.itabmed.com)